Marc Abrams
Chief Technology Officer SanegeneBio
Marc brings over 20 years of leadership experience in oligonucleotide therapeutics and targeted delivery of genetic medicines. As CTO and Head of US Operations at SanegeneBio, a clinical-stage RNAi company with R&D centers in Boston, Suzhou and Shanghai, Marc’s team supports pipeline programs across therapeutic areas and development of new delivery platforms. He previously worked as CSO of Carbon Biosciences and SVP of Discovery Research at Dicerna Pharmaceuticals (a Novo Nordisk company), as well as multiple scientific leadership roles at Merck and Co, Inc. Marc holds a PhD in Biochemistry from Thomas Jefferson University and has participated in several scientific advisory boards.
Seminars
Friday 29th January 2027
Pioneering Advancements to Push Boundaries in Patient Care
10:00 am
- Explore the technologies emerging after the first wave of RNAi success
- Assess opportunities to further improve potency and durability
- Extend the commercial and clinical impact of tissue selective RNAi therapeutics
